Chronic right heart failure
Conditions
Brief summary
Change in serum NT-proBNP level from baseline to end of treatment (Delta-NTproBNP)
Detailed description
Change in quality of life assessed by overall summary score of the Kansas City Cardiomyopathy Questionnaire (KCCQ) (a specific HF patient reported outcome questionnaire) from baseline to end of treatment, Change in RV ejection fraction (RV EF) [%] assessed in cardiac MRI from baseline to end of treatment, Change in exercise capacity assessed by the 6 min walking distance [meters] from baseline to end of treatment, Change in NYHA (New York Heart Association) class from baseline to end of treatment
Interventions
DRUGDapagliflozin Placebo tablets
DRUGDAPAGLIFLOZIN
Sponsors
Universitaetsmedizin Goettingen
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Change in serum NT-proBNP level from baseline to end of treatment (Delta-NTproBNP) | — |
Secondary
| Measure | Time frame |
|---|---|
| Change in quality of life assessed by overall summary score of the Kansas City Cardiomyopathy Questionnaire (KCCQ) (a specific HF patient reported outcome questionnaire) from baseline to end of treatment, Change in RV ejection fraction (RV EF) [%] assessed in cardiac MRI from baseline to end of treatment, Change in exercise capacity assessed by the 6 min walking distance [meters] from baseline to end of treatment, Change in NYHA (New York Heart Association) class from baseline to end of treatment | — |
Countries
Germany
Outcome results
None listed